News: IMM Immutep Receives FDA And Irb Approval In The Us For Phase Iib Tacti-003 Trial In Hnscc, page-4

Some information from Bell Potters...

Bell Potters Analyst outlook & stock picks for FY 22 in the healthcare sectors was Immutep,Genetic Signatures and mesoblast

(IMM)Immutep is developing immunotherapies for cancer and autoimmune diseases. It is the leader in LAG-3, which has emerged as the next big immuno-oncology checkpoint with recent validation from pivotal data on Bristol Myers Squibb’s relatlimab. Clinical data released recently at ASCO of IMM’s lead drug efti with Merck’s Keytruda in lung and head and neck cancer has increased our confidence in the asset. A $65m capital raise is ongoing to extend the cash runway to 4QCY23 and fund new trials including a Phase 3. We see the release of further clinical data as the key catalyst forthe stock in FY22, driving subsequent new collaborations and licensing/M&A interest.Buy (Speculative), Valuation $0.85